Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review.

Published on Jun 3, 2021in Expert Review of Anti-infective Therapy3.767
· DOI :10.1080/14787210.2021.1848545
Betsy Joseph3
Estimated H-index: 3
,
Mahmoud Dibas5
Estimated H-index: 5
+ 19 AuthorsJillienne C. Touchette1
Estimated H-index: 1
Sources
Abstract
Objectives: To systematically review the clinical literature reporting the use of Lopinavir/ritonavir (LPV/r) for the treatment of patients with COVID-19 to assess the efficacy of LPV/r for the treatment of Cornonavirus disease 19 (COVID-19). Methods: The authors systematically searched PubMed and MedRxiv databases for studies describing treatment of COVID-19 patients using LPV/r compared to other therapies. Articles were excluded if they were case reports, opinion editorials, preclinical studies, single-armed studies, not written in English, not relevant to the topic, or published before May 2020. The included outcomes were viral clearance as measured by reverse-transcription polymerase chain reaction (RT-PCR) negativity and/or improvement on chest computed tomography (CT), mortality, and adverse events (AEs). Results: Among 858 total studies, 16 studies met the inclusion criteria and were included in the qualitative review. These studies consisted of 3 randomized control trials, 3 open-label trials, and 10 observational studies. Most of these studies did not report positive clinical outcomes with LPV/r treatment. Conclusion: The systematic review revealed insufficient evidence of effectiveness and clinical benefit of LPV/r in the treatment of patients with COVID-19. Specifically, LPV/r does not appear to improve clinical outcome, mortality, time to RT-PCR negativity, or chest CT clearance in patients with COVID-19.
References37
Newest
#1Ji-Won Kim (CUA: The Catholic University of America)H-Index: 21
#2Eun Jin Kim (CUA: The Catholic University of America)H-Index: 8
Last. Hyo-Lim Hong (CUA: The Catholic University of America)H-Index: 12
view all 7 authors...
Background/aims The efficacies of lopinavir-ritonavir or hydroxychloroquine remain to be determined in patients with coronavirus disease 2019 (COVID-19). To compare the virological and clinical responses to lopinavir-ritonavir and hydroxychloroquine treatment in COVID-19 patients. Methods This retrospective cohort study included patients with COVID-19 treated with lopinavir-ritonavir or hydroxychloroquine at a single center in Korea from February 17 to March 31, 2020. Patients treated with lopin...
23 CitationsSource
#1Chong Yu (HUST: Huazhong University of Science and Technology)H-Index: 3
#2Zhiguo Zhang (HUST: Huazhong University of Science and Technology)H-Index: 53
Last. Rui Zeng (HUST: Huazhong University of Science and Technology)H-Index: 17
view all 8 authors...
BACKGROUND: During the early stages of the pandemic, some coronavirus disease (COVID-19)patients were misdiagnosed as having influenza, which aroused the concern that some deaths attributed to influenza were actually COVID-19-related. Howerver, little is known about whether coinfection with influenza contributes to severity of COVID-19 pneumonia, and the optimal therapeutic strategy for these patients. METHODS: We retrospectively studied 128 hospitalized patients with COVID-19 pneumonia. All pat...
11 CitationsSource
#1Yueping Li (Guangzhou Medical University)H-Index: 8
#2Zhiwei Xie (Guangzhou Medical University)H-Index: 5
Last. Linghua Li (Guangzhou Medical University)H-Index: 13
view all 20 authors...
Background: Antiviral therapies against the novel coronavirus SARS-CoV-2, which has caused a global pandemic of respiratory illness called COVID-19, are still lacking. Methods: Our study (NCT04252885, named ELACOI), was an exploratory randomized (2:2:1) controlled trial assessing the efficacy and safety of lopinavir/ritonavir (LPV/r) or arbidol monotherapy for treating patients with mild/moderate COVID-19. Findings: This study successfully enrolled 86 patients with mild/moderate COVID-19 with 34...
144 CitationsSource
24 CitationsSource
#1George Mihai Nitulescu (UMFCD: Carol Davila University of Medicine and Pharmacy)H-Index: 13
#2Horia Paunescu (UMFCD: Carol Davila University of Medicine and Pharmacy)H-Index: 3
Last. Aristidis Tsatsakis (UoC: University of Crete)H-Index: 68
view all 10 authors...
The major impact produced by the severe acute respiratory syndrome coronavirus�2 (SARS�CoV�2) focused many researchers attention to find treatments that can suppress transmission or ameliorate the disease. Despite the very fast and large flow of scientific data on possible treatment solutions, none have yet demonstrated unequivocal clinical utility against coronavirus disease�2019 (COVID�19). This work represents an exhaustive and critical review of all available data on potential treatments for...
62 CitationsSource
#1Zhen ZhuH-Index: 2
#2Zhaohui LuH-Index: 1
Last. Yuan XueH-Index: 2
view all 8 authors...
Abstract Lopinavir/ritonavir and arbidol have been previously used to treat acute respiratory syndrome- coronavirus 2 (SARS-CoV-2) replication in clinical practice; nevertheless, their effectiveness remains controversial. In this study, we evaluated the antiviral effects and safety of lopinavir/ritonavir and arbidol in patients with the 2019-nCoV disease (COVID-19). Fifty patients with laboratory-confirmed COVID-19 were divided into two groups: including lopinavir/ritonavir group (34 cases) and ...
219 CitationsSource
#1Periklis Panagopoulos (DUTH: Democritus University of Thrace)H-Index: 14
#2Vasilis Petrakis (DUTH: Democritus University of Thrace)H-Index: 3
Last. Dimitrios Papazoglou (DUTH: Democritus University of Thrace)H-Index: 22
view all 7 authors...
Corona Virus Disease (CoVID-19) is an emerging public health problem rapidly spread globally. New treatment options for patients with severe symptoms and ways of reducing transmission in the community are taken into consideration. A retrospective study was conducted in the Department of Infectious Diseases of Alexandroupolis (Greece) including 16 patients with CoVID-19. They were classified into two groups, A and B. Group A received lopinavir/ritonavir as a third agent in the antiviral regimen, ...
10 CitationsSource
#1Zhicheng ZhangH-Index: 3
#2Shumei WangH-Index: 1
Last. Hongyi ChenH-Index: 3
view all 12 authors...
BACKGROUND: In late December 2019, the coronavirus disease 2019�(COVID-19) first outbroke in Wuhan city, China, and has now become a global pandemic. However, there is no specific antiviral treatment for COVID-19. METHODS: This study enrolled 33 COVID-19 patients in the nineth hospital of Nanchang from January 27th to February 24th , 2020. Clinical indexes of patients upon admission/discharge were examined. Patients were divided into two groups according to different treatment plans (Danoprevir;...
8 CitationsSource
Background Pneumonia with respiratory failure represents the main cause of death in COVID-19, where hyper inflammation plays an important role in lung damage. This study aims to evaluate if tocilizumab, an anti-soluble IL-6 receptor monoclonal antibody, reduces patients’ mortality. Methods 85 consecutive patients admitted to the Montichiari Hospital (Italy) with COVID-19 related pneumonia and respiratory failure, not needing mechanical ventilation, were included if satisfying at least one among:...
161 CitationsSource
#1Ivan Hung (HKU: University of Hong Kong)H-Index: 72
#2Kwok Cheung Lung (Pamela Youde Nethersole Eastern Hospital)H-Index: 3
Last. Kwok-Yung Yuen (HKU: University of Hong Kong)H-Index: 157
view all 44 authors...
Summary Background Effective antiviral therapy is important for tackling the coronavirus disease 2019 (COVID-19) pandemic. We assessed the efficacy and safety of combined interferon beta-1b, lopinavir–ritonavir, and ribavirin for treating patients with COVID-19. Methods This was a multicentre, prospective, open-label, randomised, phase 2 trial in adults with COVID-19 who were admitted to six hospitals in Hong Kong. Patients were randomly assigned (2:1) to a 14-day combination of lopinavir 400 mg...
853 CitationsSource
Cited By2
Newest
#1Giovanny Carvalho dos Santos (UNESP: Sao Paulo State University)H-Index: 5
#5Luiz Carlos da Silva-Filho (UNESP: Sao Paulo State University)H-Index: 13
Last. Bruno Henrique Sacoman Torquato da Silva (UFU: Federal University of Uberlandia)H-Index: 5
view all 6 authors...
A virus outbreak challenges the economic, medical, and public health infrastructure worldwide. More than one virus capable of triggering diseases have been identified per year since 1972, which requires the development of new ways of treatment and prevention, however, such processes are not rapid and easy. With the pandemic scenario experienced since early 2020, several drugs with well-known purposes have gained prominence, due to speculation of their use in the treatment against the new coronav...
Source
2 CitationsSource